Impact of Platinum-based Cancer Treatment on Endothelial Function
- Conditions
- Cardiovascular ComplicationHigh Blood Pressure
- Registration Number
- NCT04681560
- Brief Summary
In this research we investigate endothelial function in cancer patients who received platinum based chemotherapy.
- Detailed Description
The goal of the study is to evaluate endothelial function in patients with platinum-based versus non-platinum-based chemotherapy.
Endothelial function was evaluated via Angioscan( the apparatus that evaluate the stiffness of vessels by pulse wave velocity) and serum levels of endothelial nitric oxide synthase (ENOS),endothelin1.
Patients with gastrointestinal, ovarian, bladder and brest cancer would be included.
Patients with malignancies were followed-up from 2 weeks to 3 month after start of chemotherapy, Medical records and hospital databases were searched for all the patients treated with different chemotherapy treatment for any kind of cancer.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
- Subject has solid cancer
- Subject is expected to start chemotherapy
- Pregnancy and lactation
- Severe impaired kidney function
- Severe hepatic impairment
- Mental disease
- Acute myocardial infarction 28 days ago or earlier
- Acute Cerebrovascular Event 1 month ago or earlier
- Rhythm disturbance that complicate pulse wave velocity evaluation
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of blood pressure Before start of chemotherapy (1 hour after including in the trial) Both systolic and diastiolic blood pressure were measured in the office in the seated position, noninvasively.
Evaluation of flow-mediated vasodilation and pulse-wave velocity Before start of chemotherapy (1 hour after including in the trial) Flow-mediated dilatation and pulse-wave velocity were measured via "Angioscan" apparatus in the seated position.The cuff inflation period of 5 min was initially decided to produce adequate hyperaemia to allow flow-mediated dilatation. The scanning period used in our trial was 1 minite before and 9 minutes after the cuff deflation.
Evaluation of concetration of ENOS and Big Endothelin in blood sampling Before start of chemotherapy (1 hour after including in the trial) Blood was collected from the cubital vein to 10.0 ml/ 6.0 ml red top tubes (without clot activator). The sample was then separated by centrifugation. The serum was frozen to -20C.
- Secondary Outcome Measures
Name Time Method Evaluation of blood pressure In range of 3 -12 weeks after start of chemotherapy (before next chepotherapy drug injection) Both systolic and diastiolic blood pressure was measured in the office in the seated position, noninvasively.
Evaluation of concetration of ENOS and Big Endothelin of blood sampling In range of 3 -12 weeks after start of chemotherapy (before next chepotherapy drug injection) Blood was collected from the cubital vein to 10.0 ml/ 6.0 ml red top tubes (without clot activator). The sample was then separated by centrifugation. The serum was frozen to -20C.
Evaluation of flow-mediated vasodilation and pulse-wave velocity In range of 3 -12 weeks after start of chemotherapy (before next chepotherapy drug injection) Flow-mediated dilatation and pulse-wave velocity were measured via "Angioscan" apparatus in the seated position.The cuff inflation period of 5 min was initially decided to produce adequate hyperaemia to allow flow-mediated dilatation. The scanning period used in our trial was 1 minite before and 9 minutes after the cuff deflation.
Trial Locations
- Locations (2)
Olga Andreeva
🇷🇺Moscow, Russian Federation
First Moscow State Medical University.
🇷🇺Moscow, Russian Federation